AbCellera Biologics
ABCL
190 hedge funds and large institutions have $1.21B invested in AbCellera Biologics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 38 reducing their positions, and 15 closing their positions.
350% more call options, than puts
Call options by funds: $49.9M | Put options by funds: $11.1M
193% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 15
95% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 38
18% more funds holding
Funds holding: 161 → 190 (+29)
1.2% more ownership
Funds ownership: 41.52% → 42.73% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4% less capital invested
Capital invested by funds: $1.26B → $1.21B (-$54.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
+$117M |
| 2 |
D.E. Shaw & Co
New York
|
+$18.4M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$16.5M |
| 4 |
CC
Casdin Capital
New York
|
+$9.87M |
| 5 |
BlackRock
New York
|
+$8.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$115M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$37.9M |
| 3 |
Millennium Management
New York
|
-$22.9M |
| 4 |
Renaissance Technologies
New York
|
-$11.6M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$7.95M |
ABCL Hedge Fund Activity: Q3 2022 in Review
190 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2022, worth a combined $1.21B — down 4.3% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ABCL positions and 15 closed out — a net gain of 29 holders — while 74 added to existing stakes and 38 trimmed.
The largest buyer was VOYA Investment Management, adding an estimated $117M. The largest seller was Allianz Asset Management, exiting entirely with an estimated $115M sold.
- 190 institutional investors held AbCellera Biologics (ABCL) as of Q3 2022, up from 161 in Q2 2022.
- Funds reported $1.21B of AbCellera Biologics stock for Q3 2022, down 4.3% quarter-over-quarter.
- 44 funds opened new AbCellera Biologics positions in Q3 2022 and 15 closed out, a net change of +29 holders.
- The largest AbCellera Biologics buyer in Q3 2022 was VOYA Investment Management, an estimated $117M added.
- The largest AbCellera Biologics seller in Q3 2022 was Allianz Asset Management, an estimated $115M sold.
Based on aggregated 13F filings for Q3 2022.